Accueil   Diary - News   All news Theranexus obtains the authorization to start a phase 1b clinical trial

Theranexus obtains the authorization to start a phase 1b clinical trial

 

Theranexus obtains the authorization to start a phase 1b clinical trial with its drug candidate THN201 in neurocognitive disorders due tu Alzheimer's disease

 

Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today it received the approval from French regulatory authorities to start a Phase Ib clinical trial with its drug candidate THN201.



Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree